Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche

The company achieved record sales for the year.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche

FY Revenues: $49.1 billion (+8%)

FY Earnings: $8.5 billion (-22%)

Comments: Pharma sales were up 11% (8% in CHF and U.S. dollars). The company achieved record sales for the year with continued growth for Avastin, Herceptin, MabThera/Rituxan, Tarceva and Xeloda, as well as Tamiflu and Lucentis sales. Genentech contributed 9% to results. Roche obtained full ownership of Genentech in March 2009. For the year, restructuring and integration costs were $2.3 billion, related to the discontinuation of a construction project at the manufacturing site at Vacaville, CA, the closure of manufacturing operations at Nutley, NJ, the closure of the R&D site at Palo Alto, CA, and costs associated with the consolidation of the U.S. administrative functions in South San Francisco.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters